M. Daley

TL;DR: Estrogen-replacement therapy prevents osteoporosis in postmenopausal women by inhibiting bone resorption, but the balance between its long-term risks and benefits remains unclear.

TL;DR: Thinness is an important risk factor for low bone mass and increased bone loss in postmenopausal women and because the response to alendronate treatment is independent of fat mass parameters, prevention of post menopausal osteoporosis can be equally achieved in thinner and heavier women.

TL;DR: Alendronate prevents bone loss in postmenopausal women under 60 years of age to nearly the same extent as estrogen-progestin and was well tolerated, with a safety profile similar to that of placebo or estrogen- Progestin.

TL;DR: In this article, four years of alendronate or estrogen-progestin therapy prevented postmenopausal bone loss and a residual effect was seen 2 years after alendralate therapy was stopped.

TL;DR: Investigation of the relation of calcium intake to bone loss in early postmenopausal women using data from the Early Postmenopausal Interventional Cohort study found more effective therapy appears to be required when the therapeutic goal is to increase or maintain BMD.